sales and profits

Adjusted EBITDA increased from €45 million in Q1 2012 to 53 million in Q1 2013 (+18%), the third best quarterly result of Oxea since its inception in 2007.

14.05.2013 • News

Momentive Specialty Chemicals Announces First Quarter 2013 Results

13.05.2013 • News

Prices, Royalties Concerns Cloud Israel Chemicals Profit

08.05.2013 • News

Brenntag Reinforces Position in Challenging Macroeconomic Environment

04.05.2013 • News

Venezuela 2012 Oil and Fuel Exports Rise, Crude Output Slips

03.05.2013 • News

Gilead Profit Rises, But Sales of Older HIV Drugs Dip

02.05.2013 • News

Teva Pharmaceutical Banks on Thrice-weekly Copaxone

01.05.2013 • News

U.S. Launch of Novo's New Insulin Faces Long Delay

30.04.2013 • News

Strong Pet Product Sales Help Zoetis Top Estimates

30.04.2013 • News

Wacker Reports Steady Start to the New Fiscal Year in Q1 2013

30.04.2013 • News

Clariant Posts Growth in Q1 2013

27.04.2013 • News

Bayer Reports Successful 2012, Q1 2013

26.04.2013 • News

AbbVie Delivers on Scorching Humira Drug Sales Growth

26.04.2013 • News

Total Profit Falls on Lower Oil Prices, Output

26.04.2013 • News

Eastman Announces Q1 2013 Financial Results

26.04.2013 • News

BASF Beats Estimates with Crop Chemicals Lift

26.04.2013 • News

Potash Corp Drops Bid for Israel Chemicals

25.04.2013 • News

Biogen Profit Beats Estimates, Raises 2013 Forecast

25.04.2013 • News

Dow Chemical Sees Farm Products Driving Profit This Year

25.04.2013 • News

U.S. Oil Production Rises for Exxon, Conoco in Q1

25.04.2013 • News

AstraZeneca Q1 Sales Tumble as Generic Losses Bite Deep

25.04.2013 • News

Lonza Business Performance on Track

25.04.2013 • News

Thermo Fisher Profit up as Life Tech awaits

25.04.2013 • News

GSK Puts Lucozade and Ribena Drink Brands up for Sale

24.04.2013 • News

Novartis Seeks Productivity Improvements with New CFO

322 more articles

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Interview

Strategic Response to a Shifting Pharma Landscape

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.